A retrospective study on risk factors affecting liver function with clozapine

A retrospective study on risk factors affecting liver function with clozapine - Effects of clozapine on liver function

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050407

Enrollment

Registered

2023-02-21

Start date

2023-02-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

treatment-resistant schizophrenia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who had received clozapine in NCNP

Exclusion criteria

Exclusion criteria: 1) Those who with defective data 2) Those who are receiving hepatic function-improving drugs prior to taking clozapine 3) Those who have elevated levels of liver enzymes prior to taking clozapine

Design outcomes

Primary

Measure	Time frame
Cumulative dose of clozapine at 4, 8, 12, 16, and 18 weeks	—

Secondary

Measure	Time frame
Sex,BMI,age, concomitant medications,etc	—

Countries

Japan

Contacts

Public ContactKaori Ishii

National Center Hospital, National Center of Neurology and Psychiatry pharmacy

yaku.ishii@ncnp.go.jp042-341-2711

Outcome results